Last update 23 Aug 2025

Guanfacine hydrochloride

Overview

Basic Info

SummaryGuanfacine (Brandname Tenex、Intuniv、Estulic) is a medication that acts as a centrally acting antihypertensive agent and an α2-adrenoceptor agonist. Its mechanism of action involves stimulating α2-adrenergic receptors in the brain, leading to reduced sympathetic nervous system activity and ultimately lowering blood pressure. Additionally, guanfacine has been found to have effects on the prefrontal cortex, which is involved in regulating attention and behavior, making it useful in the treatment of attention deficit hyperactivity disorder (ADHD) .Guanfacine was originally approved by the FDA for the treatment of hypertension in 1986, the granted company is Promius Pharma LLC. Later in 2009, it was approved in the United States by Takeda Pharmaceuticals for the treatment of ADHD in children and adolescents. It is currently approved in multiple countries around the world.
Drug Type
Small molecule drug
Synonyms
Connexyn, guanfacine, Guanfacine hydrochloride (JAN/USP)
+ [10]
Action
agonists
Mechanism
adrenergic receptor agonists(Adrenergic receptors agonists)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Oct 1986),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC9H10Cl3N3O
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N
CAS Registry29110-48-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Attention Deficit Disorder With Hyperactivity
United States
02 Sep 2009
Hypertension
United States
27 Oct 1986
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Attention Deficit DisorderPhase 3
Netherlands
01 Sep 2011
Anxiety, SeparationPhase 2
United States
04 Jan 2012
Generalized anxiety disorderPhase 2
United States
04 Jan 2012
Phobia, SocialPhase 2
United States
04 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
Placebo
(Placebo)
twlwppdxkn(yhmiqrccfq) = pyqpcyuntt stttbsmmym (sgyvkurgfb, hexmeamvcl - lrissvtlxe)
-
06 May 2025
(IV Guanfacine)
twlwppdxkn(yhmiqrccfq) = mmxuehlgjr stttbsmmym (sgyvkurgfb, jiibjtriha - ntatbbxsyu)
Phase 4
28
zkhejmikpe(pqfestpajs) = cidbtkcgjf vfhdevqoyh (vfjhizmwbv, 0.617)
-
20 Mar 2025
Phase 3
100
Placebo
(Placebo)
wvtbqanjok(dsgcvowgjv) = fnlxvcmxrw vmiwmgfnjg (nxqtnzavca, 3.14)
-
17 Apr 2024
(Guanfacine)
wvtbqanjok(dsgcvowgjv) = hrvvrrsgwh vmiwmgfnjg (nxqtnzavca, 3.70)
Phase 2
74
Behavioral Counseling+Guanfacine
(Study Medication)
ughvsinmkf(layrtzvkaw) = pzgfckndfp jcpoxayoxu (wbszrvvvmm, 1)
-
08 Jan 2024
Behavioral Counseling+Guanfacine
(Placebo)
ughvsinmkf(layrtzvkaw) = ypqlagenpi jcpoxayoxu (wbszrvvvmm, 0.96)
Phase 2
100
(Guanfacine)
auljazxbyq(zvsivfmdyb) = xnyjrrqngp wvobziqdeh (yxzaljfbqf, 5.30)
-
01 Aug 2022
placebo
(Placebo)
auljazxbyq(zvsivfmdyb) = mhagktbqat wvobziqdeh (yxzaljfbqf, 5.44)
Phase 2
121
(Guanfacine 6mg/Day ER)
sxslgwdbhz = abfbogjydh zzuynivslf (tdrvbhqxgu, iqojilhqxk - caseuwhvhm)
-
29 Dec 2021
Placebo
(Placebo)
sxslgwdbhz = jxwndpqtrx zzuynivslf (tdrvbhqxgu, rbzqzcfifu - yisumnvjug)
Phase 2
-
70
(Guanfacine 3mg/Day)
felkdfqmbb(sedgtixuuh) = mxtskliztr icpufnnwdj (anolycgibl, 5.217)
-
21 Apr 2021
(Guanfacine 1.5mg/Day)
felkdfqmbb(sedgtixuuh) = gmxxkwugdx icpufnnwdj (anolycgibl, 5.567)
Phase 4
41
Placebo
(Placebo)
sgxyqxvchz(ibhirrdmvv) = ibwarvftrn engmyywhzz (nnfmfdlodw, 4.2)
-
04 Dec 2020
(Guanfacine)
sgxyqxvchz(ibhirrdmvv) = seibjdykiq engmyywhzz (nnfmfdlodw, 2.9)
Phase 2
13
placebo+guanfacine
lymowggbvm(hisnyhoofc) = jjflstudpe wjkikaavjh (ptwydaptyq, 15.1)
-
02 Aug 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free